Holen Sie sich die Stockscreener-App
0.7027
3.52%
0.0239
Schlusskurs vom Vortag:
$0.6788
Offen:
$0.6652
24-Stunden-Volumen:
73,958
Relative Volume:
0.13
Marktkapitalisierung:
$17.49M
Einnahmen:
$522.00K
Nettoeinkommen (Verlust:
$-10.80M
KGV:
-1.2234
EPS:
-0.5744
Netto-Cashflow:
$-8.78M
1W Leistung:
-15.21%
1M Leistung:
+12.88%
6M Leistung:
-40.95%
1J Leistung:
-46.77%
1-Tages-Spanne:
$0.6512
$0.72
1-Wochen-Bereich:
$0.6506
$0.8122
52-Wochen-Spanne:
$0.46
$1.8955
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Firmenname
Lexaria Bioscience Corp
Sektor
Branche
Telefon
250-765-6424
Adresse
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.7027 | 16.89M | 522.00K | -10.80M | -8.78M | -0.5744 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.14 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.60 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
703.52 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.31 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.80 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lexaria Bioscience Corp Aktie (LEXX) Neueste Nachrichten
Lexaria launches 2026 research program for drug delivery tech - Investing.com Nigeria
Buybacks Report: Will Lexaria Bioscience Corp Equity Warrant outperform tech stocksJuly 2025 Sector Moves & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Buybacks Report: Is Lexaria Bioscience Corp Equity Warrant currently under institutional pressureAnalyst Upgrade & Weekly Breakout Stock Alerts - baoquankhu1.vn
Aug Wrap: Can Lexaria Bioscience Corp Equity Warrant sustain earnings growth2025 Market Sentiment & Stock Market Timing Techniques - baoquankhu1.vn
Lexaria launches 2026 research program for drug delivery tech By Investing.com - Investing.com Canada
Lexaria Announces New R&D Plans for 2026 - Investing News Network
Lexaria Launches 2026 R&D Push to Advance GLP-1 and Cannabidiol Drug Delivery - TipRanks
Lexaria Bioscience Corp Announces New Research and Development Program - marketscreener.com
LEXX Initiates 2026 R&D Program to Enhance Pharma Innovations - GuruFocus
Biotech tests new oral GLP-1 formulas against Wegovy tablets - Stock Titan
Update Recap: Will Smith Douglas Homes Corp benefit from rate cuts2025 Big Picture & Long Hold Capital Preservation Plans - baoquankhu1.vn
Is Lexaria Bioscience Corp. exposed to currency risksMarket Performance Recap & Technical Pattern Alert System - mfd.ru
Lexaria Bioscience: Improving Oral Weight-Loss Drug Tolerability - The Globe and Mail
Aug Wrap: Is Lexaria Bioscience Corp a strong candidate for buy and holdEarnings Recap Summary & Weekly High Potential Stock Alerts - baoquankhu1.vn
Lexaria Bioscience: Oral Drug Delivery Technology Targets Next-Gen Weight Loss Market - The Globe and Mail
LEXX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Aug Intraday: Can Lexaria Bioscience Corp expand into new marketsJuly 2025 Movers & Low Risk Growth Stock Ideas - baoquankhu1.vn
US Market Wrap: What are the risks of holding Hanover Bancorp IncMarket Growth Summary & Safe Capital Allocation Plans - baoquankhu1.vn
Update Report: Can Lexaria Bioscience Corp Equity Warrant sustain earnings growth2025 Dividend Review & Low Risk Investment Opportunities - baoquankhu1.vn
Published on: 2026-02-20 23:25:19 - baoquankhu1.vn
Will Lexaria Bioscience Corp. Equity Warrant stock go up in YEARJuly 2025 Selloffs & Entry Point Confirmation Signals - mfd.ru
Published on: 2026-02-20 04:22:15 - baoquankhu1.vn
Aug Intraday: Is Lexaria Bioscience Corp exposed to currency risksJuly 2025 Chart Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Aug Action: Will NHICU outperform tech stocksDip Buying & Verified Short-Term Trading Plans - baoquankhu1.vn
Is Lexaria Bioscience Corp. likely to announce a buyback2025 Support & Resistance & Entry Point Strategy Guides - mfd.ru
How Lexaria Bioscience Corp. Equity Warrant stock performs in interest rate cyclesQuarterly Earnings Summary & AI Optimized Trade Strategies - mfd.ru
Why Lexaria Bioscience Corp. stock could rally in 2025July 2025 Update & Real-Time Market Trend Scan - mfd.ru
Can Lexaria Bioscience Corp. ride the EV wave2025 AllTime Highs & AI Powered Market Entry Strategies - mfd.ru
Will Lexaria Bioscience Corp. stock attract ESG investorsMarket Trend Report & Entry and Exit Point Strategies - mfd.ru
LEXX PE Ratio & Valuation, Is LEXX Overvalued - Intellectia AI
Aug Momentum: Can Lexaria Bioscience Corp. Equity Warrant stock outperform in 2025 bull marketWatch List & AI Optimized Trading Strategy Guides - mfd.ru
Can Lexaria Bioscience Corp. Equity Warrant sustain earnings growthJuly 2025 PostEarnings & Low Risk High Win Rate Stock Picks - mfd.ru
Research Analysts Set Expectations for LEXX Q2 Earnings - Defense World
Analysts Set Expectations for LEXX FY2028 Earnings - Defense World
Is Lexaria Bioscience Corp. Equity Warrant exposed to political riskRecession Risk & AI Driven Stock Price Forecasts - mfd.ru
Quarterly Earnings: Is Lexaria Bioscience Corp a strong candidate for buy and holdMarket Growth Summary & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Lexaria Bioscience Stock Price, News, Quote & History - Investing News Network
Bear Alert: Can Lexaria Bioscience Corp expand into new markets2025 Market WrapUp & Weekly Top Gainers Trade List - baoquankhu1.vn
Aug Swings: What is Lexaria Bioscience Corp Equity Warrants revenue forecastJuly 2025 Spike Watch & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Hedge Fund Moves: Does Lexaria Bioscience Corp have declining or rising EPSWeekly Stock Recap & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Lexaria Bioscience Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Lexaria’s Oral Liraglutide Shows Comparable Performance and Fewer Side Effects in Human Study - TipRanks
Lexaria Bioscience (LEXX) Demonstrates Promising Results in Late - GuruFocus
Lexaria Announces Positive Final Results from Human Pilot Study #5 - Investing News Network
Lexaria Announces Positive Final Results From Human Pilot Study #5 - The Joplin Globe
Finanzdaten der Lexaria Bioscience Corp-Aktie (LEXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):